Known targets — ChEMBL curated mechanism
ABL1BMXBRAFBTKCHRNA4CHRNB2CSNK1EEGFRERBB2F10FLT1FLT3FLT4IGF1RINSRITKJAK3KDRKITOPRM1PARP1PARP2PDGFRBPIK3CDRAF1RETSLC18A2TECTXKdacAdacBdacCftsImrcAmrcBmrdArplArplBrplCrplDrplErplFrplJrplKrplLrplMrplNrplOrplPrplQrplRrplSrplTrplUrplVrplWrplXrplYrpmArpmBrpmCrpmDrpmErpmFrpmGrpmHrpmIrpmJrpsArpsBrpsCrpsDrpsErpsFrpsGrpsHrpsIrpsJrpsKrpsLrpsMrpsNrpsOrpsPrpsQrpsRrpsSrpsTrpsUykgMykgO
The experimentally established mechanism targets of None. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 19)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP2D6 | P10635 | 1/20 | 0.46 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.46 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.44 |
| ▸ | KIF11 | P52732 | 5/20 | 0.44 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.43 |
| ▸ | CA12 | O43570 | 1/20 | 0.42 |
| ▸ | CA9 | Q16790 | 1/20 | 0.42 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.42 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.42 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.42 |
| ▸ | MEN1 | O00255 | 2/20 | 0.41 |
| ▸ | GAA | P10253 | 2/20 | 0.41 |
| ▸ | SLC1A3 | P43003 | 1/20 | 0.40 |
| ▸ | SLC1A2 | P43004 | 1/20 | 0.40 |
| ▸ | SLC1A1 | P43005 | 1/20 | 0.40 |
| ▸ | BACE1 | P56817 | 1/20 | 0.40 |
| ▸ | RECQL | P46063 | 1/20 | 0.40 |
| ▸ | KEAP1 | Q14145 | 1/20 | 0.39 |
| ▸ | NFE2L2 | Q16236 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1307366 | 0.88 | ALDH1A1 (0.44) | CYP2D6MAPK1ALDH1A1KIF11KMT2A | |
| SCHEMBL4199918 | 0.81 | ALPI (0.52) | KIF11SLC1A3SLC1A2SLC1A1 | |
| SCHEMBL4199926 | 0.81 | ALPI (0.52) | KIF11SLC1A3SLC1A2SLC1A1 | |
| Phenylalanine SCHEMBL10429981 | 0.80 | SLC7A5 (0.63) | CYP2D6MAPK1ALDH1A1KIF11GAA | |
| Dl-Phenylalanine SCHEMBL28023088 | 0.80 | SLC7A5 (0.63) | CYP2D6MAPK1ALDH1A1KIF11GAA | |
| SCHEMBL3930881 | 0.80 | ALDH1A1 (0.45) | ALDH1A1KIF11KMT2ACA12CA9 | |
| SCHEMBL18075129 | 0.79 | KIF11 (0.48) | CYP2D6MAPK1ALDH1A1KIF11CYP1A2 | |
| Phenylalanine SCHEMBL20267852 | 0.78 | SLC7A5 (0.61) | CYP2D6MAPK1ALDH1A1KIF11GAA | |
| D-Phenylalanine SCHEMBL20267959 | 0.78 | SLC7A5 (0.61) | CYP2D6MAPK1ALDH1A1KIF11GAA | |
| Dl-Phenylalanine SCHEMBL20267856 | 0.78 | SLC7A5 (0.61) | CYP2D6MAPK1ALDH1A1KIF11GAA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20090203918-A1 | METHOD FOR PRODUCING ENANTIOMERIC FORM OF 2,3-DIAMINOPROPIONIC ACID DERIVATIVES | SANOFI-AVENTIS DEUTSCHLAND GMBH (DE) | 2009-08-13 | — | — | US | disclosed |
| US-7514578-B2 | Method for producing enantiomeric form of 2,3-diaminopropionic acid derivatives | SANOFI-AVENTIS DEUTSCHLAND GMBH (DE) | 2009-04-07 | — | — | US | disclosed |
| US-20070238778-A1 | METHOD FOR PRODUCING ENANTIOMERIC FORM OF 2,3-DIAMINOPROPIONIC ACID DERIVATIVES | SANOFI-AVENTIS DEUTSCHLAND GMBH (DE) | 2007-10-11 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090203918-A1 | METHOD FOR PRODUCING ENANTIOMERIC FORM OF 2,3-DIAMINOPROPIONIC ACID DERIVATIVES | DDC, ADM2, MTHFD2 | CYP2D6 49/4885MAPK1 3619/4885ALDH1A1 130/4885 |
| US-20070238778-A1 | METHOD FOR PRODUCING ENANTIOMERIC FORM OF 2,3-DIAMINOPROPIONIC ACID DERIVATIVES | DDC, DAO, ADM2 | CYP2D6 74/4885MAPK1 3753/4885ALDH1A1 171/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.